Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14365/3235| Title: | Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) | Authors: | Saad, F. Armstrong, A. J. Thiery-Vuillemin, A. Oya, M. Shore, N. D. Procopio, G. Arslan, C. |
Publisher: | Elsevier | Abstract: | [Abstract Not Available] | Description: | Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- SEP 09-13, 2022 -- ELECTR NETWORK | URI: | https://hdl.handle.net/20.500.14365/3235 | ISSN: | 0923-7534 1569-8041 |
| Appears in Collections: | WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| 2340.pdf Restricted Access | 157.18 kB | Adobe PDF | View/Open Request a copy |
CORE Recommender
WEB OF SCIENCETM
Citations
6
checked on Nov 20, 2024
Page view(s)
50
checked on Nov 18, 2024
Download(s)
6
checked on Nov 18, 2024
Google ScholarTM
Check
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.